IOPtima

Company Overview

Snapshot

Founded in January 2005, IOPtima operates with 1–10 employees. The company has secured $7.2 million in total capital across one funding round from three investors. IOPtima was acquired by Chengdu Kanghong Pharmaceutical Group in September 2018.

Business overview

IOPtima is a Health Tech & Life Sciences company specializing in the development of minimally invasive surgical ophthalmic devices. Its core product, the IOPtimate, is a surgical system that uses CO2 laser technology to treat glaucoma by reducing internal eye pressure without penetration. The company also offers patented eye drops for ocular surface diseases. IOPtima serves the healthcare industry, including hospitals and clinics, and operates within the medical devices and pharma & medical biotechnology sectors.

Strategic signal

In September 2018, Chengdu Kanghong Pharmaceutical Group solidified its ownership of IOPtima by acquiring an additional 41% stake for $17.2 million, increasing its total stake to 60%. This move signals a strategic consolidation by Chengdu Kanghong Pharma to integrate IOPtima's innovative ophthalmic devices, particularly the IOPtimate system for glaucoma treatment, into its portfolio, indicating strong confidence in the technology's market potential and future growth under its ownership.

Company Intelligence Q&A

What was the most significant corporate event for IOPtima?

In September 2018, IOPtima was acquired by Chengdu Kanghong Pharmaceutical Group. This followed an earlier investment where Chengdu Kanghong Pharma acquired a 41% stake for $17.2 million, bringing its total ownership to 60%.

When did IOPtima receive regulatory approval for its IOPtiMate system in Canada?

In December 2015, Bio Light Israeli Life Sciences Investments Ltd. received approval from the Canadian Medical Devices Bureau for its IOPtiMate system, allowing commercialization of the glaucoma treatment system in Canada.

What product did IOPtima launch in October 2017?

In October 2017, IOPtima launched Lipitear, a phospholipid-based microemulsion designed to restore the ocular surface and enhance corneal re-epithelization after surgery, reducing symptoms of ocular surface disorder.

What was the initial investment by Chengdu Kanghong Pharma in IOPtima?

In April 2017, Chengdu Kanghong Pharma invested $7 million in IOPtima for a 19% stake, valuing the company at $30 million. This also granted Chengdu Kanghong Pharma an exclusive license to market IOPtima's product in China.

What product did IOPtima launch in July 2017?

In July 2017, IOPtima launched the iLid CO2 laser kit, designed for oculoplastic surgeons to perform CO2 laser-assisted blepharoplasty, offering benefits such as reduced bruising, swelling, and a shorter recovery period.